Navigation Links
Isis Pharmaceuticals Announces Its Participation at the Upcoming,ACC 56th Annual Scientific Session in New Orleans and Its Live,Analyst/Investor Webcast Presentation

CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces that results from three Phase 2 studies of ISIS 301012, including effects of ISIS 301012 in homozygous familial hypercholesterolemic (HoFH) patients, will be the subjects of three upcoming presentations at the of Cardiology (ACC), March 24-27 in New Orleans. Planned presentations include effects of ISIS 301012 in patients both as monotherapy and added to stable statin therapy. An overall summary of the Phase 2 program results for ISIS 301012 will be provided at the March 27 Analyst/Investor webcast presentation, along with a summary of Isis' development plan for ISIS 301012. ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.

    Sunday, March 25, 2007


    Session:          1206:  Vascular Disease, Hypertension and Prevention --

                      V-cast Poster


    Track:            ACC.Vascular Disease, Hypertension, and Prevention


    Room:             Hall H


    Presentation:     1206-278


    Abstract:         Statin-Like, Dose-Dependent Reductions in LDL-C and

                      Apolipoprotein B With ISIS 301012, an Antisense

                      Inhibitor of Apolipoprotein B, in Subjects With

                      Polygenic Hypercholesterolemia


    Monday, March 26, 2007


    Session:          603:  Common Challenges in Preventive Cardiology

                      (7:00 - 8:30 a.m. CT)


    Track:            ACC.Symposium


    Room:             Auditorium B


    Presentation:     603-8


    Time:             8:15 - 8:30 a.m.


    Speaker:          Dr. Evan A. Stein


    Title:            High Low-Density Lipoprotein Cholesterol on Three Drugs*

                      *to include preliminary results of an ongoing study

                      evaluating ISIS 301012 in HoFH patients on concurrent

                      maximally tolerated lipid-lowering therapies


    Session:          820:  Clinical Trials of 
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , July 12 For the second consecutive year, Orthocare ... prestigious R&D 100 Award.  Orthocare Innovations received this award for its Galileo™ ... persons who have experienced lower limb loss, injury or disease. , ... (Logo:   http://photos.prnewswire.com/prnh/20100712/DA33752LOGO ) , ...
... MURRIETA, Calif. , July 12 NogWorld LLC, a pioneer in ... to easily connect and access medical providers. , ... The DocNog California App was recently featured in the "New and Noteworthy" section of ... additional mobile platforms, such as Android and BlackBerry. , ...
Cached Medicine Technology:Orthocare Innovations Receives Prestigious R&D 100 Award for Novel Web-Based Rehabilitation Outcomes Assessment System 2DocNog California Mobile App Automates Medical Provider Search 2
(Date:4/22/2014)... school sport in the United States with 1 million ... the Center for Injury Research and Policy at Nationwide ... the occurrence and distribution patterns of basketball-related injuries treated ... setting among adolescents and teens. , The study, published ... examined data relating to adolescents 13-19 years of age ...
(Date:4/22/2014)... decades researchers have characterized a set of clock genes ... all types of species, from flies to humans. Over ... surmise there are more. A team from the Perelman ... if big-data approaches could find them. , To ... PhD, professor of Pharmacology and first author Ron Anafi, ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
(Date:4/22/2014)... German . ... but their mode of action is complex: In low ... behavior, while at high concentrations they can cause "oxidative ... how redox signaling unfolds in single cells and organelles ... developed jointly by the teams of LMU Professor Martin ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:Neuroimaging: Live from inside the cell 2
... asthma, may predispose to dry mouth syndrome ( xerostomia) and ... to examine whether there was a connection between// the two ... caries. , ,In 655 patients between ages 1 ... and filled teeth were significantly higher in those who had ...
... of bypass patients suffer mental decline after bypass surgery, ... that the heart-lung machine is the culprit. But according ... suffered by many heart-bypass patients several months after surgery ... in the operating room after all. ,The ...
... the eye’s retina is well on its way to ... such as Retinitis Pigmentosa and age-related degeneration of the ... , The implant works for eye diseases in which healthy ... the eye’s photoreceptors. These receptors convert images into electric ...
... found drug users often drifted off in the middle of ... told already.The drug cannabis people used,// the more they abated ... come from one of the largest studies carried out into ... is not representative of all drug takers and involved more ...
... created using information taken from a monkey gene ``dramatically ... laboratory experiment. The researchers believe the substance, which ... cells, but was lost to humans because of an ... University of California, Los Angeles, medical school, said he ...
... bacteria carrying a specific toxin can cause a severe, ... and young adults.// They have so far linked infection ... marked by widespread tissue destruction in the respiratory tract. ... Dr. Jerome Etienne of the National Reference Center for ...
Cached Medicine News:Health News:Medications linked to xerostomia and caries, 2Health News:Scientists found ancient Human Germ Killer 2Health News:Toxin connected to 'Flesh-eating' Pneumonia in Kids 2
This legless table has adjustable height and round post. Pad sold separately....
This table has a rectangular top, adjustable height, integral leg, and rail clamp.,Standard 2" (5 cm) pad included....
Built-in accessory rail clamps quickly mount to any standard O.R. table or stretcher. The leg, available in single post or double tee adjusts with a simple twist. Optional armrests are available. Wal...
... The powered torso and leg ... Trauma Table simultaneously lift body ... lift mechanism raises and lowers ... precise positioning. A wide range ...
Medicine Products: